The European Leadership Summit on Chronic Care

3-4 December, 2007, Amsterdam, The Netherlands
Organised under the high patronage of the European Commission, the event will convene senior executives from key organisations advancing chronic care in Europe including providers, payers, suppliers, customers, policy-makers and health officials.

The European Leadership Summit on Chronic Care is the forum where government and industry leaders share successful initiatives and best practices. So far, the agenda includes case studies from 12 different countries.

Through the support of our partner organizations, we are creating a truly international event, reaching key health leaders in over 40 countries. An international delegation will enjoy this two-day networking opportunity, featuring visionary keynote addresses, controversial debates, implementation case studies, tutorials and informal roundtable discussions.

Four focused summits will give attendees a unique opportunity to discuss pertinent issues in depth and determine actionable plans with their colleagues:

  • IT Infrastructures, Electronic Health Records and Chronic Care
  • Aligning Financial Incentives and Restructuring Care
  • Telehealth and Remote Monitoring
  • Empowering Patients and Supporting Self-Care

Two best practice seminars will also explore disease specific initiatives for:

  • Diabetes
  • Cardiovascular and Lung Diseases

For further information and registration, please visit:
http://www.worldcongress.com/events/HL07080/

Most Popular Now

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

Sandoz announces new global 'Act4Biosimilars' init…

Sandoz, a global leader in generic and biosimilar medicines, announced the launch of a new global initiative called 'Act4Biosimilars' to help address health inequity and ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...